Advertisement

Topics

Sandoz's biosimilar of Roche's MabThera/Rituxan wins EU approval

06:04 EDT 20 Jun 2017 | SmartBrief

The European Commission has approved Sandoz's Rixathon, a biosimilar version of Roche Holding's monoclonal antibody drug MabT -More

Original Article: Sandoz's biosimilar of Roche's MabThera/Rituxan wins EU approval

NEXT ARTICLE

More From BioPortfolio on "Sandoz's biosimilar of Roche's MabThera/Rituxan wins EU approval"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...